Matthew Harrison
Stock Analyst at Morgan Stanley
(3.50)
# 804
Out of 5,182 analysts
711
Total ratings
49.54%
Success rate
3.97%
Average return
Main Sectors:
Stocks Rated by Matthew Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $769 → $796 | $746.00 | +6.70% | 60 | Apr 10, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $171 → $175 | $138.55 | +26.31% | 45 | Apr 10, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $176.02 | +13.62% | 57 | Apr 10, 2026 | |
| INSM Insmed | Upgrades: Overweight | $166 → $212 | $142.79 | +48.47% | 21 | Mar 30, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $40 → $42 | $20.71 | +102.80% | 14 | Mar 26, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $50 → $49 | $21.08 | +132.45% | 15 | Mar 11, 2026 | |
| R Ryder System | Maintains: Positive | $235 → $250 | $221.38 | +12.93% | 2 | Feb 13, 2026 | |
| MRNA Moderna | Maintains: Equal-Weight | $30 → $28 | $54.68 | -48.79% | 27 | Dec 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $1,070 → $1,110 | $828.35 | +34.00% | 27 | Dec 4, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $37 → $41 | $28.78 | +42.46% | 16 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $4 | $5.02 | -20.32% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $98 | $54.10 | +81.15% | 23 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $460 → $439 | $435.65 | +0.77% | 41 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $20 | $21.17 | -5.53% | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6.2 → $6 | $5.70 | +5.26% | 10 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $5 | $0.75 | +569.25% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $37.63 | +48.82% | 2 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $55 | $29.35 | +87.39% | 2 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $3 | $2.55 | +17.65% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $39.53 | -72.17% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 | $3.35 | +108.96% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $32 | $28.30 | +13.07% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $19 | $3.67 | +417.71% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $1.71 | -41.52% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $10 | $23.59 | -57.60% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 → $8 | $7.99 | +0.13% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $44 | $28.86 | +52.46% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $3.47 | +274.64% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $80 | $23.70 | +237.55% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $60 | $4.81 | +1,147.40% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $203 → $216 | $102.12 | +111.52% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.38 | +14.16% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $3.85 | +29.87% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $182 | $208.99 | -12.91% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $9 | $40.41 | -77.73% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $282 | $349.39 | -19.29% | 38 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $210 | $320.13 | -34.40% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $52 | $27.22 | +91.04% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $175 → $173 | $234.54 | -26.24% | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $156 → $120 | $24.52 | +389.40% | 17 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $145 → $148 | $10.01 | +1,378.52% | 19 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $82 | $115.46 | -28.98% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $71 → $66 | $58.96 | +11.94% | 4 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $39 | $5.95 | +555.46% | 4 | Aug 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $46 | $48.48 | -5.12% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $35 | $9.33 | +275.13% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $207 → $275 | $903.99 | -69.58% | 2 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $3.18 | +497.48% | 1 | Jun 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $62 | $9.19 | +574.65% | 12 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.57 | +4.10% | 3 | Feb 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $89 → $83 | $95.32 | -12.92% | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $10 | $65.42 | -84.71% | 4 | Sep 10, 2018 |
Regeneron Pharmaceuticals
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $769 → $796
Current: $746.00
Upside: +6.70%
Gilead Sciences
Apr 10, 2026
Maintains: Overweight
Price Target: $171 → $175
Current: $138.55
Upside: +26.31%
Biogen
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $176.02
Upside: +13.62%
Insmed
Mar 30, 2026
Upgrades: Overweight
Price Target: $166 → $212
Current: $142.79
Upside: +48.47%
Denali Therapeutics
Mar 26, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $20.71
Upside: +102.80%
Legend Biotech
Mar 11, 2026
Maintains: Overweight
Price Target: $50 → $49
Current: $21.08
Upside: +132.45%
Ryder System
Feb 13, 2026
Maintains: Positive
Price Target: $235 → $250
Current: $221.38
Upside: +12.93%
Moderna
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $30 → $28
Current: $54.68
Upside: -48.79%
argenx SE
Dec 4, 2025
Maintains: Overweight
Price Target: $1,070 → $1,110
Current: $828.35
Upside: +34.00%
Pharvaris
Dec 4, 2025
Maintains: Overweight
Price Target: $37 → $41
Current: $28.78
Upside: +42.46%
Nov 12, 2025
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $5.02
Upside: -20.32%
Oct 28, 2025
Maintains: Overweight
Price Target: $104 → $98
Current: $54.10
Upside: +81.15%
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $460 → $439
Current: $435.65
Upside: +0.77%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $15 → $20
Current: $21.17
Upside: -5.53%
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $6.2 → $6
Current: $5.70
Upside: +5.26%
Mar 12, 2025
Maintains: Overweight
Price Target: $15 → $5
Current: $0.75
Upside: +569.25%
Feb 18, 2025
Upgrades: Buy
Price Target: $56
Current: $37.63
Upside: +48.82%
Jan 31, 2025
Maintains: Buy
Price Target: $57 → $55
Current: $29.35
Upside: +87.39%
Nov 26, 2024
Downgrades: Underweight
Price Target: $10 → $3
Current: $2.55
Upside: +17.65%
Jun 21, 2024
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $39.53
Upside: -72.17%
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $3.35
Upside: +108.96%
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $28.30
Upside: +13.07%
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $3.67
Upside: +417.71%
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.71
Upside: -41.52%
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $23.59
Upside: -57.60%
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $7.99
Upside: +0.13%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $28.86
Upside: +52.46%
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $3.47
Upside: +274.64%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $140 → $80
Current: $23.70
Upside: +237.55%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $100 → $60
Current: $4.81
Upside: +1,147.40%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $102.12
Upside: +111.52%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.38
Upside: +14.16%
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $3.85
Upside: +29.87%
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $208.99
Upside: -12.91%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $40.41
Upside: -77.73%
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $349.39
Upside: -19.29%
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $320.13
Upside: -34.40%
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $27.22
Upside: +91.04%
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $234.54
Upside: -26.24%
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $24.52
Upside: +389.40%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $10.01
Upside: +1,378.52%
Nov 29, 2021
Maintains: Equal-Weight
Price Target: $88 → $82
Current: $115.46
Upside: -28.98%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $71 → $66
Current: $58.96
Upside: +11.94%
Aug 18, 2021
Maintains: Overweight
Price Target: $43 → $39
Current: $5.95
Upside: +555.46%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $51 → $46
Current: $48.48
Upside: -5.12%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $33 → $35
Current: $9.33
Upside: +275.13%
Aug 5, 2021
Maintains: Overweight
Price Target: $207 → $275
Current: $903.99
Upside: -69.58%
Jun 24, 2021
Initiates: Buy
Price Target: $19
Current: $3.18
Upside: +497.48%
Mar 8, 2021
Maintains: Overweight
Price Target: $67 → $62
Current: $9.19
Upside: +574.65%
Feb 24, 2021
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.57
Upside: +4.10%
Jan 6, 2020
Maintains: Equal-Weight
Price Target: $89 → $83
Current: $95.32
Upside: -12.92%
Sep 10, 2018
Assumes: Equal-Weight
Price Target: $10
Current: $65.42
Upside: -84.71%